Fundraising Fox
Meddenovo
Lyon, FR · Founded 2023 · 10 employees on LinkedIn · 1 known investors
Find your way into Meddenovo
Sign up to see every warm intro you have to Meddenovo
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Meddenovo team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Meddenovo develops Mexa, an AI-powered platform for de novo design of cyclic peptide drug candidates. The company serves pharmaceutical partners seeking to discover novel peptide therapeutics for oncology, radiopharmaceuticals, and metabolic diseases.
Founders & leadership
Meddenovo was founded in 2023 by Ilke Ugur Marion.
Investors · 1
ACT Venture Partnerslisted by ACT Venture PartnersAmsterdam · $550K – $1.6M
How we know: funding news · tech.eu · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountPre-seedJul 2024
ACT Venture Partners (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Meddenovo do?
- Meddenovo develops Mexa, an AI-powered platform for de novo design of cyclic peptide drug candidates. The company serves pharmaceutical partners seeking to discover novel peptide therapeutics for oncology, radiopharmaceuticals, and metabolic diseases.
- Who founded Meddenovo?
- Meddenovo was founded by Ilke Ugur Marion in 2023.
- Who are Meddenovo's investors?
- Meddenovo's investors include ACT Venture Partners.
- Where is Meddenovo headquartered?
- Meddenovo is headquartered in Lyon, FR.